SCHEMBL3757738

SCHEMBL3757738

CCCCNC(=O)C1c2ccccc2C(=O)N1C(c1ccc(F)cc1)c1cccnc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.60
KCNH2 Q12809 1/20 0.49
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
FPR1 P21462 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PRMT5 O14744 2/20 0.40
WDR77 Q9BQA1 2/20 0.40
POLB P06746 1/20 0.39
ALDH1A1 P00352 2/20 0.39
P2RX7 Q99572 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749983 0.87 KCNA5 (0.56) KCNA5KCNH2TDP1SMN1; SMN2FPR1
SCHEMBL3749111 0.86 KCNA5 (0.60) KCNA5KCNH2TDP1SMN1; SMN2FPR1
SCHEMBL3755711 0.85 KCNA5 (0.58) KCNA5KCNH2SMN1; SMN2ALDH1A1MAPT
SCHEMBL3750582 0.82 KCNA5 (0.64) KCNA5KCNH2TDP1SMN1; SMN2ALDH1A1
SCHEMBL3756971 0.79 KCNA5 (0.51) KCNA5KCNH2SMN1; SMN2CYP2C19POLB
SCHEMBL3754031 0.79 KCNA5 (0.60) KCNA5KCNH2SMN1; SMN2ALDH1A1P2RX7
SCHEMBL3747535 0.78 KCNA5 (0.54) KCNA5SMN1; SMN2POLBALDH1A1MAPT
SCHEMBL3760166 0.76 KCNA5 (0.48) KCNA5KCNH2ALDH1A1P2RX7KDM4E
SCHEMBL3744491 0.76 KCNA5 (0.68) KCNA5KCNH2PRMT5WDR77P2RX7
SCHEMBL4204175 0.76 KCNA5 (0.56) KCNA5KCNH2TDP1ALDH1A1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885KCNH2 2/4885TDP1 2095/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885KCNH2 2/4885TDP1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.